Boston Scientific Corporation $BSX Shares Acquired by Acadian Asset Management LLC

Key Points

• Acadian Asset Management LLC increased its stake in Boston Scientific Corporation by 434.9%, owning 606,229 shares valued at approximately $61.14 million at the end of Q1.
• Insider transactions show a significant decrease in ownership among executives, with EVP Joseph Michael Fitzgerald selling 50,000 shares for over $5.2 million and a notable 21.90% reduction in his position.
• Boston Scientific's earnings report revealed an EPS of $0.75, surpassing estimates, and strong revenue growth of 22.8% year-over-year, leading analysts to maintain a consensus "Buy" rating with a target price of $117.79.

Acadian Asset Management LLC lifted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 434.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 606,229 shares of the medical equipment provider's stock after purchasing an additional 492,891 shares during the quarter. Acadian Asset Management LLC's holdings in Boston Scientific were worth $61,142,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. HM Payson & Co. grew its position in shares of Boston Scientific by 1.4% during the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after purchasing an additional 98 shares in the last quarter. Park Square Financial Group LLC increased its holdings in Boston Scientific by 5.2% in the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after buying an additional 103 shares in the last quarter. HHM Wealth Advisors LLC increased its stake in shares of Boston Scientific by 13.2% during the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock worth $89,000 after purchasing an additional 103 shares in the last quarter. Rise Advisors LLC grew its stake in Boston Scientific by 13.9% during the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock valued at $85,000 after acquiring an additional 103 shares in the last quarter. Finally, Forum Financial Management LP grew its stake in Boston Scientific by 0.8% during the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock valued at $1,357,000 after acquiring an additional 112 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Performance

Shares of BSX traded down $1.63 during trading hours on Friday, hitting $102.71. The stock had a trading volume of 10,541,837 shares, compared to its average volume of 6,118,901. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The firm has a market capitalization of $152.19 billion, a PE ratio of 61.14, a PEG ratio of 2.51 and a beta of 0.65. The stock has a fifty day moving average price of $104.86 and a 200 day moving average price of $102.26.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total value of $5,271,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,802,597.06. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BSX shares. Barclays increased their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Truist Financial increased their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Robert W. Baird boosted their target price on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Leerink Partners assumed coverage on Boston Scientific in a report on Monday, June 16th. They set an "outperform" rating and a $118.00 target price on the stock. Finally, Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and a consensus price target of $118.04.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.